Table 3.
Absolute mean changes in the development index of the MP-R scale at week 16 and Sequential Analysis
| Secondary analysis: Absolute mean changes in the DI (age equivalent in months) of the MP-R Scale | |||||
|---|---|---|---|---|---|
| Age equivalents (months) | Group A (Placebo-Minocycline) (N = 11) | Group B1 (Minocycline-Placebo) (N = 11) | Group B2 (Minocycline-Minocycline) (N = 10) | p value | |
| Development index | Baseline | 12·55 (6·53) | 13·09 (6·31) | 10·80 (6·33) | 0·699 |
| Week 16 | 15·55 (5·93) | 13·90 (6·65) | 12·00 (7·64) | 0·495 | |
| Absolute mean change | 3·00 (3·63) | 0·72 (2·56) | 1·20 (5·53) | 0·401 | |
| Secondary analysis: Development index change after 8 week or 16 week total treatment duration with minocycline | |||||
| Age equivalents(months) | Minocycline 8 weeksa (N = 22) | Minocycline-16 weeksb (N = 10) | Absolute mean differences, 95% CI | ||
| Development index | Absolute mean change | 1·86 (3·35) | 1·20 (5·53) | 0·663, 95% CI (−2·55–3·88) | |
| Secondary analysis: Period effect analysis in the cross-over substudy | |||||
| PERIOD 1 (N = 22) | PERIOD 2 (N = 22) | Absolute mean differences, 95% CI, p value | |||
| Development index | Absolute mean change | 2·21 (3·37) | − 0·34 (3·24) | 2·55, 95% CI (0·80–5·05) | |
a Minocycline treatment for 8 weeks include Group A and Group B1 mean changes at week 16 following a total 8-week treatment duration, regardless of the actual placebo-minocycline sequence of treatment;
b This corresponds to mean changes at week 16 for Group B2, the subset of 10 patients who received a total of 16 weeks treatment with minocycline